Search research articles
Contact Us
Filters
Showing results (891-900 of 902) with videos related to
Page
of 91
Sort By:
Free Radical Biology & Medicine
|
March 16, 2011
Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy
Lan-Feng Dong, Victoria J A Jameson, David Tilly, et al.
Science (New York, N.Y.)
|
October 12, 2019
High thermoelectric performance in low-cost SnS<sub>0.91</sub>Se<sub>0.09</sub> crystals
Wenke He, Dongyang Wang, Haijun Wu, et al.
Orthopaedic Surgery
|
June 8, 2018
Complications and Prevention Strategies of Oblique Lateral Interbody Fusion Technique
Zhong-You Zeng, Zhao-Wan Xu, Deng-Wei He, et al.
Elife
|
February 15, 2017
Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells
Lan-Feng Dong, Jaromira Kovarova, Martina Bajzikova, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer
|
January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)
Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Frontiers in Immunology
|
March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβ
Yunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Liver Cancer
|
July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study
Lin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Page
of 91
Search research articles
Search
Showing results (891-900 of 902) with videos related to
Sort By:
Page
of 91
Free Radical Biology & Medicine
|
March 16, 2011
Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy
Lan-Feng Dong, Victoria J A Jameson, David Tilly, et al.
Science (New York, N.Y.)
|
October 12, 2019
High thermoelectric performance in low-cost SnS<sub>0.91</sub>Se<sub>0.09</sub> crystals
Wenke He, Dongyang Wang, Haijun Wu, et al.
Orthopaedic Surgery
|
June 8, 2018
Complications and Prevention Strategies of Oblique Lateral Interbody Fusion Technique
Zhong-You Zeng, Zhao-Wan Xu, Deng-Wei He, et al.
Elife
|
February 15, 2017
Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells
Lan-Feng Dong, Jaromira Kovarova, Martina Bajzikova, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer
|
January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)
Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Frontiers in Immunology
|
March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβ
Yunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Liver Cancer
|
July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study
Lin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Page
of 91